{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:13:21Z","timestamp":1790187201953,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.phrs.2022.106111","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T11:50:13Z","timestamp":1645098613000},"page":"106111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Comparative effectiveness of traditional Chinese medicine and angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and sodium glucose cotransporter inhibitors in patients with diabetic kidney disease: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"177","author":[{"given":"Lili","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runyu","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongyue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruonan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2022.106111_bib1","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1053\/j.ajkd.2014.08.001","article-title":"Diabetic kidney disease: a report from an ADA consensus conference","volume":"64","author":"Tuttle","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.phrs.2022.106111_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.phrs.2022.106111_bib3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3390\/jcm9030813","article-title":"Special issue \u201cdiabetic nephropathy: diagnosis, prevention and treatment\u201d","volume":"9","author":"Ruiz-Ortega","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib4","first-page":"522","article-title":"Expert consensus on early prediction and diagnosis of diabetic kidney disease","volume":"60","author":"Zhang","year":"2021","journal-title":"Chin. J. Intern. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib5","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease","volume":"4","author":"Strippoli","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2022.106111_bib6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","author":"National Kidney Foundation","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.phrs.2022.106111_bib7","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","article-title":"A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors","volume":"33","author":"Sen","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2022.106111_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2022.106111_bib9","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.kint.2018.04.025","article-title":"Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and sup- presses oxidative stress in the kidneys of diabetic mice","volume":"94","author":"Tanaka","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2022.106111_bib10","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","article-title":"A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice","volume":"94","author":"Zhang","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2022.106111_bib11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2022.106111_bib12","first-page":"7330","article-title":"Adverse effects associated with currently commonly used antifungal agents: a network meta-analysis and systematic review","volume":"69","author":"Yang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106111_bib13","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions version 6.0. Cochrane, 2019. \u3008http:\/\/www.training.cochrane.org\/handbook\u3009. (Accessed 1 July 2021)."},{"key":"10.1016\/j.phrs.2022.106111_bib14","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ Clin. Res. Ed."},{"key":"10.1016\/j.phrs.2022.106111_bib15","article-title":"Clinical efficacy and safety of Shashen Maidong decoction in the treatment of pediatric mycoplasma pneumonia: a systematic review and meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.phrs.2022.106111_bib16","unstructured":"Expert Group of Nephrology Branch of Chinese Medical Association, Chinese guidelines for clinical diagnosis and treatment of diabetic nephropathy, Chin. J. Nephrol., 37(3), 2021, pp. 255\u2013304."},{"key":"10.1016\/j.phrs.2022.106111_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/937549","article-title":"The effect of chinese herbal medicine on albuminuria levels in patients with diabetic nephropathy: a systematic review and meta-analysis","volume":"2013","author":"Xiao","year":"2013","journal-title":"Evid. Based Complement Altern. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib18","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jep.2013.11.028","article-title":"Clinical trials of traditional Chinese medicine in the treatment of diabetic nephropathy--a systematic review based on a subgroup analysis","volume":"151","author":"Liu","year":"2014","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.phrs.2022.106111_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1509063","article-title":"Liuwei Dihuang pills enhance the effect of western medicine in treating diabetic nephropathy: a meta-analysis of randomized controlled trials","volume":"2016","author":"Lin","year":"2016","journal-title":"Evid. Based Complement Altern. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib20","article-title":"Effectiveness comparisons of traditional Chinese medicine on treating diabetic nephropathy proteinuria: a systematic review and meta-analysis","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.phrs.2022.106111_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/j.ajkd.2012.07.011","article-title":"Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial","volume":"61","author":"Fernandez","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.phrs.2022.106111_bib22","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2022.106111_bib23","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/dom.13639","article-title":"Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: a prospective, randomized, controlled trial","volume":"21","author":"Ruggenenti","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2022.106111_bib24","article-title":"Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2022.106111_bib25","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.16.4.597","article-title":"Renal function changes in microalbuminuria normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors","volume":"16","author":"Romero","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2022.106111_bib26","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2022.106111_bib27","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1463-1326.2005.00514.x","article-title":"The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency","volume":"8","author":"Tong","year":"2006","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2022.106111_bib28","first-page":"245","article-title":"Clinical observation of Shenluoan decoction for treating obese patients with early diabetic nephropathy","volume":"46","author":"Wang","year":"2015","journal-title":"Chin. Tradit. Herb. Drugs"},{"key":"10.1016\/j.phrs.2022.106111_bib29","first-page":"894","article-title":"A comparative study of efficacy of enalapril versus telmisartan in patients with diabetic nephropathy","volume":"10","author":"Arpitha","year":"2020","journal-title":"Natl. J. Physiol. Pharm. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106111_bib30","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib31","first-page":"88","article-title":"Xiaozheng Tongluo decoction combine with irbesartan tablets treat diabetic nephropathy randomized parallel group study","volume":"28","author":"Bai","year":"2014","journal-title":"J. Pract. Tradit. Chin. Intern. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib32","first-page":"2214","article-title":"Efficacy of irbesartan combined with empagliflozin for diabetic kidney disease","volume":"42","author":"Chen","year":"2020","journal-title":"Zhejiang Med. J."},{"key":"10.1016\/j.phrs.2022.106111_bib33","first-page":"269","article-title":"Observation of the effect of perindopril in the treatment of early diabetic nephropathy in the elderly","volume":"11","author":"Chen","year":"2003","journal-title":"Chin. J. Arterioscler."},{"key":"10.1016\/j.phrs.2022.106111_bib34","first-page":"1018","article-title":"Clinical observation on phase III and IV diabetic nephropathy treated with Yiqi Yangyin Xiaozheng Tongluo formula","volume":"35","author":"Chen","year":"2020","journal-title":"China J. Tradit. Chin. Med. Pharm."},{"key":"10.1016\/j.phrs.2022.106111_bib35","first-page":"768","article-title":"Clinical study of telmisartan on renal protection in patients with early diabetic nephropathy","volume":"33","author":"Fu","year":"2016","journal-title":"J. Clin. Intern. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib36","first-page":"881","article-title":"A randomized controlled trial of the combination of Yiqibushen decoction with tripterygium glycosides and valsartan for the treatment of spleen and kidney deficiency type diabetic nephropathy","volume":"16","author":"Fu","year":"2015","journal-title":"Chin. J. Integr. Tradit. West. Nephrol."},{"key":"10.1016\/j.phrs.2022.106111_bib37","first-page":"1047","article-title":"Low-dose benazepril combined with Losartan in the treatment of 63 cases of non-hypertensive diabetic nephropathy","volume":"38","author":"Gao","year":"2009","journal-title":"Shaanxi Med. J."},{"key":"10.1016\/j.phrs.2022.106111_bib38","first-page":"5","article-title":"Effect of treatment of tonify qi of kidney, disperse blood stasis and dredge collateral, clear heart and purging turbidity on diabetic nephropathy serum creatinine","volume":"13","author":"Gao","year":"2015","journal-title":"Chin. Med. Mod. Distance Educ. China"},{"key":"10.1016\/j.phrs.2022.106111_bib39","first-page":"1885","article-title":"Clinical research on Zhenwu decoction in the treatment of diabetic nephropathy of spleen and kidney deficiency syndrome","volume":"31","author":"Guo","year":"2016","journal-title":"Acta Chin. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib40","first-page":"779","article-title":"Clinical efficacy of Yiqi Yangyin Xiaozheng Tongluo Fang on patients with stage IV diabetic nephropathy","volume":"39","author":"Guo","year":"2016","journal-title":"J. Beijing Univ. Tradit. Chin. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib41","first-page":"155","article-title":"Clinical study on Yiqi Yangyin Huoxue Tang for diabetic nephropathy with qi-blood deficiency syndrome","volume":"51","author":"He","year":"2019","journal-title":"J. New Chin. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib42","first-page":"80","article-title":"Clinical research of Tangshenjian in the treatment of type 2 diabetic nephropathy","volume":"24","author":"Hu","year":"2018","journal-title":"J. Basic Chin. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib43","first-page":"737","article-title":"Clinical study of valsartan combined with benazepril in the treatment of diabetic nephropathy","volume":"10","author":"Hu","year":"2006","journal-title":"Clin. Focus"},{"key":"10.1016\/j.phrs.2022.106111_bib44","first-page":"1897","article-title":"Observation on the curative effect of TCM treatment of diabetic nephropathy","volume":"25","author":"Huang","year":"2016","journal-title":"Mod. J. Integr. Tradit. Chin. West. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib45","first-page":"946","article-title":"Clinical observation on Buyuan Tongluo decoction combined with irbesartan for 31 cases of diabetic nephropathy at stage \u2162","volume":"55","author":"Huang","year":"2014","journal-title":"J. Tradit. Chin. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib46","first-page":"47","article-title":"Effect of irbesartan combined with liuwei dihuang decoction on urine microalbumin in early diabetic nephropathy","volume":"12","author":"Li","year":"2014","journal-title":"J. Community Med."},{"key":"10.1016\/j.phrs.2022.106111_bib47","first-page":"1029","article-title":"Analysis of 53 cases of diabetic nephropathy treated by tripterygium polyglycosides and Danggui Huangqi decoction","volume":"38","author":"Li","year":"2014","journal-title":"Heilongjiang Med. J."},{"key":"10.1016\/j.phrs.2022.106111_bib48","first-page":"1181","article-title":"Effect of lisinopril and losartan on early-stage nephropathy and retinopathy in type 1 diabetes","volume":"20","author":"Li","year":"2010","journal-title":"China J. Mod. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib49","first-page":"869","article-title":"Effect of Tangshen-Huazhuo recipe on the levels of serum transforming growth factor \u03b21 and platelet derived growth factor in patients with \u2163 stage of diabetic nephropathy","volume":"36","author":"Li","year":"2014","journal-title":"Int. J. Tradit. Chin. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib50","first-page":"481","article-title":"Benazepril combined with irbesartan in the treatment of 40 cases of diabetic nephropathy with hypertension","volume":"29","author":"Li","year":"2010","journal-title":"Her. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib51","article-title":"Observation on the efficacy of combined treatment of irbesartan and benazepril in the treatment of early diabetic nephropathy","volume":"12","author":"Liu","year":"2012","journal-title":"Gems Health"},{"key":"10.1016\/j.phrs.2022.106111_bib52","first-page":"327","article-title":"Study on the secondary prevention of nephropathy in patients with normal blood pressure and non-insulin-dependent diabetes","volume":"6","author":"Liu","year":"1999","journal-title":"Chin. J. Diabetes"},{"key":"10.1016\/j.phrs.2022.106111_bib53","first-page":"188","article-title":"Clinical study on treatment of diabetic nephropathy with Wenyang Gushen Huayu decoction","volume":"20","author":"Liu","year":"2017","journal-title":"Diabetes New World"},{"key":"10.1016\/j.phrs.2022.106111_bib54","first-page":"229","article-title":"The effect of Benazepril in treatment of the patients with early diabetic nephropathy with normotensive and microalbuminuria","volume":"2","author":"Niu","year":"2008","journal-title":"China Trop. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib55","first-page":"10","article-title":"Observations on curative effect of Jiangtang Kangshentang decoction combined with western medicine in treating diabetic nephropathy","volume":"2","author":"Pang","year":"2008","journal-title":"Guangxi J. Tradit. Chin. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib56","first-page":"1028","article-title":"The effect of combination therapy with valsartan and benazepril for early diabetic nephropathy","volume":"8","author":"Shui","year":"2007","journal-title":"J. Chin. Physician"},{"key":"10.1016\/j.phrs.2022.106111_bib57","unstructured":"X.Z. Sun, Clinical Study on Treatment of Early and Clinical Diabetic Nephropathy by TCM Syndrome Differentiation, Guangzhou University of Traditional Chinese Medicine, 2011."},{"key":"10.1016\/j.phrs.2022.106111_bib58","first-page":"1934","article-title":"Clinical research on curative effect of Jiangtang Kangshen decoction combined with western medicine in treating diabetic nephropathy at stage IV","volume":"41","author":"Tang","year":"2014","journal-title":"Liaoning J. Tradit. Chin. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib59","unstructured":"J.L. Wang, Clinical Study on Treatment of Diabetic Nephropathy of Deficiency of Qi and Yin and Blood Stasis by Xiaoke Shenbing Decoction, Shanxi University of Chinese Medicine, 2016."},{"key":"10.1016\/j.phrs.2022.106111_bib60","unstructured":"J.J. Wang, Clinical Observation on Treatment of Early Diabetic Nephropathy by Xiaoxianxiong Decoction and Buyang Huanwu Decoction, Tianjin Medical University, 2016."},{"key":"10.1016\/j.phrs.2022.106111_bib61","first-page":"257","article-title":"Clinical study of losartan combined with captopril in patients with early diabetic nephropathy","volume":"4","author":"Wang","year":"2005","journal-title":"Anhui Med. Pharm. J."},{"key":"10.1016\/j.phrs.2022.106111_bib62","first-page":"30","article-title":"Clinical study of losartan combined with captopril in patients with diabetic nephropathy","volume":"1","author":"Wang","year":"2006","journal-title":"Anhui Med. Pharm. J."},{"key":"10.1016\/j.phrs.2022.106111_bib63","first-page":"245","article-title":"Clinical observation of Shenluoan decoction for treating obese patients with early diabetic nephropathy","volume":"46","author":"Wang","year":"2015","journal-title":"Chin. Tradit. Herb. Drugs"},{"key":"10.1016\/j.phrs.2022.106111_bib64","first-page":"11","article-title":"Clinical study of Bushenjiedu decoction in treating 36 patients with stage \u2163 diabetic nephropathy","volume":"31","author":"Wang","year":"2009","journal-title":"Hebei J. Tradit. Chin. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib65","first-page":"71","article-title":"Benazepril hydrochloride adjuvant treatment of 43 cases of early diabetic nephropathy","volume":"20","author":"Wei","year":"2011","journal-title":"China Pharm."},{"key":"10.1016\/j.phrs.2022.106111_bib66","first-page":"141","article-title":"Application of valsartan in the treatment of early renal failure in non-diabetic nephropathy","volume":"17","author":"Wu","year":"2003","journal-title":"China J. Mod. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib67","unstructured":"H. Yang, Clinical Study of Yiqi Yangyin Xiaozheng Tongluo Recipe in Treating Diabetes-Diabetes Nephropathy with Deficiency of Qi and Yin and Stasis of Collateral, Hebei Medical University, 2014."},{"key":"10.1016\/j.phrs.2022.106111_bib68","first-page":"37","article-title":"The effect of perindopril in treatment of early diabetic nephropathy with normal blood pressure and microalbuminuria","volume":"12","author":"Yao","year":"2001","journal-title":"Chin. J. Intern. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib69","first-page":"54","article-title":"Study on the clinical effect of valsartan combined with benazepril in the treatment of diabetic nephropathy","volume":"22","author":"Yao","year":"2012","journal-title":"Chin. J. Postgrad. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib70","first-page":"5562","article-title":"Fosinopril combined with losartan in the treatment of 92 cases of diabetic nephropathy","volume":"32","author":"Yao","year":"2012","journal-title":"Chin. J. Gerontol."},{"key":"10.1016\/j.phrs.2022.106111_bib71","first-page":"3","article-title":"Clinical study of tongluoyiqi decoction in treatment of diabetic nephropathy with qi deficiency and blood stasis syndrome","volume":"41","author":"Yu","year":"2019","journal-title":"Hubei J. Tradit. Chin. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib72","first-page":"191","article-title":"Curative effect analysis of telmisartan in the adjuvant therapy of diabetic nephropathy","volume":"12","author":"Zhang","year":"2015","journal-title":"Pract. J. Clin. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib73","first-page":"230","article-title":"Clinical observation on therapeutic effects of combined use of Rhodiola rosea and losartan in treating diabetic nephropathy","volume":"8","author":"Zhao","year":"2008","journal-title":"J. Clin. Nephrol."},{"key":"10.1016\/j.phrs.2022.106111_bib74","first-page":"7","article-title":"Study on the efficacy of irbesartan in aged patients with early diabetic nephropathy","volume":"6","author":"Zhong","year":"2005","journal-title":"Anthol. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib75","first-page":"182","article-title":"The effect of benazepril combined with irbesartan in the treatment of diabetic nephropathy","volume":"37","author":"Lei","year":"2016","journal-title":"Guangdong Med. J."},{"key":"10.1016\/j.phrs.2022.106111_bib76","first-page":"962","article-title":"Clinical comparative study of early diabetic nephropathy treated with Yiqi Yangyin Xiaozheng Tongluo recipe and irbesartan tablets","volume":"16","author":"Chen","year":"2015","journal-title":"Chin. J. Integr. Tradit. West. Nephrol."},{"key":"10.1016\/j.phrs.2022.106111_bib77","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib78","first-page":"2827","article-title":"Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials","volume":"26","author":"Maione","year":"2011","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"10.1016\/j.phrs.2022.106111_bib79","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1093\/ndt\/gfy001","article-title":"Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis","volume":"33","author":"Cai","year":"2018","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.phrs.2022.106111_bib80","doi-asserted-by":"crossref","first-page":"f6008","DOI":"10.1136\/bmj.f6008","article-title":"Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis","volume":"347","author":"Wu","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2022.106111_bib81","article-title":"Clinical efficacy and safety of Chinese herbal medicine for the treatment of patients with early diabetic nephropathy: a protocol for systematic review and meta-analysis","volume":"99","author":"Yang","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.phrs.2022.106111_bib82","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3109\/0886022X.2015.1009820","article-title":"Use of Ophiocordyceps sinensis (syn. Cordyceps sinensis) combined with angiotensin-converting enzyme inhibitors (ACEI)\/angiotensin receptor blockers (ARB) versus ACEI\/ARB alone in the treatment of diabetic kidney disease: a meta-analysis","volume":"37","author":"Luo","year":"2015","journal-title":"Ren. Fail."},{"key":"10.1016\/j.phrs.2022.106111_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.eujim.2020.101197","article-title":"Combination of oral tripterygium glycosides and angiotensin II receptor blockers for treatment of clinical stage diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"39","author":"Wang","year":"2020","journal-title":"Eur. J. Integr. Med."},{"key":"10.1016\/j.phrs.2022.106111_bib84","article-title":"Efficacy and safety of Salvia miltiorrhiza (Salvia miltiorrhiza Bunge) and ligustrazine injection in the adjuvant treatment of early-stage diabetic kidney disease: a systematic review and meta-analysis","volume":"281","author":"Zhang","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.phrs.2022.106111_bib85","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2022.106111_bib86","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2022.106111_bib87","article-title":"Effects of the modified DASH diet on adults with elevated blood pressure or hypertension: a systematic review and meta-analysis","volume":"8","author":"Guo","year":"2021","journal-title":"Front. Nutr."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822000561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822000561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:36:09Z","timestamp":1760913369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822000561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":87,"alternative-id":["S1043661822000561"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106111","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of traditional Chinese medicine and angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and sodium glucose cotransporter inhibitors in patients with diabetic kidney disease: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106111"}}